New hope for rare cervical cancer: Triple-Drug trial launches

NCT ID NCT06654011

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (IN10018, nab-paclitaxel, and cadonilimab) in 25 women with a rare, aggressive cervical cancer that has spread or returned. The goal is to see if this treatment can shrink tumors or slow the disease. Participants must have already tried at least one chemotherapy regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical adenocarcinoma endocervical type cervical mucinous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL ADENOCARCINOMA GASTRIC-TYPE ENDOCERVICAL ADENOCARCINOMA

Contacts and locations

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China
Xiangyang Central Hospital
RECRUITING

Xiangyang, Hubei, 441000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.